Saturday 17 October 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.10
0.21
−6.34%
Follow CLNN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
289.81 | 289.36 | 428.39 | 387.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.54) | (12.06) | (12.68) | (29.47) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
326.54 | 331.12 | 506.01 | 431.06 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.75) | (3.57) | (3.75) | (5.34) | |
EV/FCF |
(3.75) | (3.56) | (3.75) | (5.32) | |
Quick Ratio |
0.95 | 0.48 | 0.88 | 2.00 | |
Current Ratio |
1.53 | 0.83 | 1.94 | 3.07 | |
Net Debt/EBITDA |
(1.49) | (1.17) | (6.10) | (1.73) | |
Debt/Assets |
70.75% | 74.68% | 75.42% | 79.47% | |
Debt/Equity |
(1.28) | (0.77) | (0.87) | (0.74) | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.45 | 0.52 | 0.56 | 0.19 | |
Capex/Depreciation |
(0.03) | (0.08) | 0.00 | 0.00 | |
Interest Coverage |
(8.70) | (10.05) | (2.61) | (7.69) | |
Research and Development Expense of Revenue |
23,420.00% | 7,146.75% | 2,193.33% | 3,856.67% | |
Selling, General and Administrative Expense of Revenue |
14,333.33% | 2,657.14% | 11,646.67% | 2,144.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11,353.33% | 1,772.73% | 8,746.67% | 1,155.56% | |
Graham Net Nets |
(0.35) | (0.46) | (0.48) | (0.43) | |
Graham Number |
9.57 | 10.22 | 10.78 | 12.55 | |
Earnings Yield |
(56.22%) | (44.29%) | (64.91%) | (56.82%) | |
Free Cash Flow Yield |
(30.03%) | (32.12%) | (31.54%) | (20.91%) | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.01 | |
Operating CF per Share |
(0.39) | (0.49) | (0.39) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.49) | (0.39) | (0.21) | |
Cash per Share |
0.77 | 0.53 | 0.51 | 0.78 | |
Shareholders Equity per Share |
(1.20) | (1.78) | (1.62) | (2.00) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.20) | (1.78) | (1.62) | (2.00) | |
Free Cash Flow |
(4.00) | (4.83) | (4.53) | (2.59) | |
Working Capital |
4.37 | (1.80) | 6.29 | 10.06 | |
Capital Expenditures |
(0.01) | (0.03) | — | 0.00 | |
Net Current Asset Value |
(21.99) | (26.75) | (27.45) | (32.90) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.73 | 0.36 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.05 | |
Average Payables |
1.52 | 1.07 | 1.36 | 0.99 | |
Average Inventory |
0.09 | 0.05 | 0.05 | 0.06 | |
Average Assets |
26.94 | 22.73 | 23.49 | 22.58 | |
Average Common Equity |
(8.24) | (13.22) | (11.89) | (16.66) |
Columns are period end dates